A Phase 1/2, Open-Label Study of BBT-176, a Triple mutation targeting EGFR TKI, in Patients with NSCLC who Progressed after Prior EGFR TKI Therapy
BBT-176
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase 1/2, Open-Label Study of BBT-176, a Triple mutation targeting EGFR TKI, in Patients with NSCLC who Progressed after Prior EGFR TKI Therapy ### Output: BBT-176